Profile data is unavailable for this security.
About the company
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
- Revenue in USD (TTM)0.00
- Net income in USD-16.91m
- Incorporated2017
- Employees6.00
- LocationExicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
- Phone+1 (847) 673-1700
- Fax+1 (847) 556-6411
- Websitehttps://www.exicuretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veritas Farms Inc | 730.65k | -6.15m | 2.62m | 17.00 | -- | 12.95 | -- | 3.59 | -0.1319 | -0.1319 | 0.0136 | 0.0013 | 0.0877 | 0.8064 | 7.80 | 42,979.41 | -69.02 | -72.11 | -123.21 | -93.59 | -220.09 | 24.07 | -787.27 | -177.79 | 0.1392 | -5.56 | 0.95 | -- | -63.42 | -0.9427 | 23.68 | -- | -52.93 | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.63m | 2.00 | -- | 0.3735 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Aridis Pharmaceuticals Inc | 22.36m | -1.14m | 2.67m | 37.00 | -- | -- | -- | 0.1196 | -0.1845 | -0.1845 | 0.7074 | -0.2648 | 2.40 | -- | 58.45 | 604,297.30 | -12.24 | -120.16 | -- | -678.29 | -- | -- | -5.11 | -1,559.63 | -- | -- | -- | -- | 101.37 | 29.16 | 34.43 | -- | -34.84 | -- |
| Aditxt Inc | 506.45k | -41.45m | 2.70m | 47.00 | -- | 0.2717 | -- | 5.33 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Sentient Brands Holdings Inc | 0.00 | -818.63k | 2.70m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Altamira Therapeutics Ltd | 118.49k | -8.17m | 2.71m | 10.00 | -- | 0.2464 | -- | 22.88 | -31.70 | -26.75 | 0.2412 | 4.91 | 0.0151 | 34.05 | 32.30 | 11,849.23 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 2.79m | 9.00 | -- | 0.3656 | -- | 0.2267 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Exicure Inc | 0.00 | -16.91m | 2.86m | 6.00 | -- | 0.9424 | -- | -- | -2.16 | -2.16 | 0.00 | 0.3504 | 0.00 | -- | -- | 0.00 | -96.91 | -41.52 | -109.98 | -55.78 | -- | -- | -- | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 2.89m | 24.00 | -- | -- | -- | 0.2031 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 2.91m | 21.00 | -- | 0.2922 | -- | 0.6197 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.57m | 2.93m | -- | -- | -- | -- | -- | -0.0188 | -0.0188 | 0.00 | -0.058 | 0.00 | -- | -- | -- | -390.77 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -6.05 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Livewire Ergogenics Inc | 67.98k | -1.09m | 2.98m | 1.00 | -- | -- | -- | 43.78 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 3.03m | 17.00 | -- | 51.03 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| DSwiss Inc | 1.68m | 144.71k | 3.12m | 11.00 | 21.57 | 13.30 | 15.97 | 1.86 | 0.0007 | 0.0007 | 0.0081 | 0.0011 | 4.43 | 189.17 | 35.95 | 152,321.80 | 38.27 | -8.69 | 79.40 | -45.47 | 32.65 | 25.55 | 8.64 | -2.47 | 2.04 | 66.93 | 0.1198 | -- | -20.50 | 46.20 | -688.36 | -- | -66.17 | -- |
Data as of Jun 14 2024. Currency figures normalised to Exicure Inc's reporting currency: US Dollar USD
3.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 65.60k | 0.76% |
| Geode Capital Management LLCas of 31 Mar 2024 | 56.52k | 0.65% |
| Northwestern University (Investment Management)as of 31 Mar 2024 | 52.15k | 0.60% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 40.09k | 0.46% |
| Millennium Management LLCas of 31 Mar 2024 | 34.80k | 0.40% |
| Virtu Americas LLCas of 31 Mar 2024 | 27.04k | 0.31% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 22.70k | 0.26% |
| Citadel Securities LLCas of 31 Mar 2024 | 18.16k | 0.21% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 12.80k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 7.03k | 0.08% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
